| ATG2B Protein | |
|---|---|
| Protein Name | ATG2B (Autophagy Related 2B) |
| Gene | [ATG2B](/genes/atg2b) |
| UniProt ID | Q9Y5P9 |
| Molecular Weight | ~208 kDa |
| Subcellular Localization | ER, autophagosome membrane |
| Protein Family | ATG2 family |
ATG2B (Autophagy-Related Protein 2B) is a key component of the autophagy machinery, specifically involved in the early stages of autophagosome formation. It participates in the recruitment of lipid membranes to the growing phagophore, the precursor to the autophagosome[1]. ATG2B has garnered attention in neurodegeneration research due to the central role of autophagy in clearing misfolded proteins and damaged organelles[2].
ATG2B is a large protein with multiple domains that mediate its function in autophagy. The protein contains an N-terminal region that interacts with the autophagosomal membrane and a C-terminal region that binds to lipid droplets and the endoplasmic reticulum[3].
In the autophagy process, ATG2B works alongside ATG2A in mammals, functioning as a tether that connects the expanding phagophore to lipid sources. ATG2B facilitates the transfer of lipids from the ER to the forming autophagosome, a critical step for membrane expansion[4].
Autophagy is impaired in Alzheimer's disease, contributing to the accumulation of amyloid-beta plaques and tau tangles. ATG2B expression is altered in AD brain tissue, with some studies showing decreased levels that could impair autophagosome formation[5].
The autophagy-lysosomal pathway is crucial for clearing tau aggregates. ATG2B dysfunction may contribute to tau pathology by reducing the capacity for autophagic clearance. Enhancing ATG2B function has been proposed as a therapeutic strategy to restore autophagy in AD[6].
In Parkinson's disease, autophagy is critical for clearing damaged mitochondria (mitophagy) and alpha-synuclein aggregates. ATG2B participates in general autophagy and may contribute to these selective autophagy pathways[7].
Genetic studies have linked ATG2B variants to PD risk in some populations, suggesting that ATG2B dysfunction could contribute to disease pathogenesis. Animal models with ATG2B deficiency show increased vulnerability to PD-relevant toxins[8].
ATG2B may play roles in other neurodegenerative conditions characterized by protein aggregation, including Huntington's disease, ALS, and frontotemporal dementia. The shared dependence on autophagy for clearing aggregate-prone proteins makes ATG2B relevant across these conditions[9].
Enhancing ATG2B function or expression could boost autophagy and improve clearance of toxic protein aggregates. Small molecules that promote ATG2B activity or restore defective autophagy are under investigation. However, the challenge lies in achieving beneficial autophagy enhancement without disrupting normal cellular functions[10].
Tamura et al. ATG2A/B in autophagosome formation. Journal of Molecular Biology. 2020. ↩︎ ↩︎
Yamamoto et al. Autophagy in neurodegenerative diseases. Nature Reviews Neurology. 2021. ↩︎ ↩︎
Kotani et al. The Atg2 protein is a component of the autophagy machinery. Proceedings of the National Academy of Sciences. 2018. ↩︎ ↩︎
Osawa et al. ATG2 transfers lipids for autophagosome formation. Nature Structural & Molecular Biology. 2019. ↩︎ ↩︎
Liu et al. ATG2B expression in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2022. ↩︎ ↩︎
Wang et al. Autophagy and tau clearance in Alzheimer's disease. Neurobiology of Disease. 2021. ↩︎
Yan et al. ATG2B in Parkinson's disease models. Cell Death & Disease. 2022. ↩︎
Zhang et al. ATG2B genetic variants and Parkinson's disease risk. Movement Disorders. 2021. ↩︎
Menzies et al. Autophagy and neurodegeneration. Annual Review of Neuroscience. 2017. ↩︎
Levine et al. Targeting autophagy in neurodegenerative diseases. Nature Reviews Drug Discovery. 2023. ↩︎